Skip to main content
    I

    InspireMD Inc (NSPR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.60
    -0.04 (-6.85%)

    Market Cap: $30.13M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    InspireMD Inc (NSPR) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    InspireMD (NSPR) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, InspireMD reported EPS of -$0.11, above the -$0.15 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    76%(26/34)
    Avg Surprise
    +19.77%
    Streak
    5 Q

    Upcoming Estimates

    Reports Mar 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.13
    Range-$0.14 - -$0.12
    5 analysts
    Revenue Consensus
    $2.70M
    Range$2.25M - $3.15M
    5 analysts

    Next Report

    NSPR has an expected report date of Mar 16, 2027.

    NSPR Earnings Call

    The latest NSPR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 34 quarters below that had an estimate, NSPR beat 26, missed 5 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $2.24M, down 11.1% from $2.52M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.11-$0.15-$0.16 - -$0.15+26.67%BeatN/A33 up, 0 downNov 12, 2026$2.24M
    Jun 30, 2026-$0.17-$0.20-$0.21 - -$0.19+15.00%BeatN/A30 up, 2 downAug 14, 2026$1.77M
    Mar 31, 2026-$0.16-$0.18-$0.19 - -$0.16+11.11%BeatN/A32 up, 0 downMay 4, 2026$3.40M
    Dec 31, 2025-$0.14-$0.19-$0.22 - -$0.18+26.32%BeatN/A32 up, 0 downMar 18, 2026$3.15M
    Sep 30, 2025-$0.17-$0.19-$0.22 - -$0.17+10.53%BeatN/A22 up, 0 downNov 4, 2025$2.52M
    Jun 30, 2025-$0.26-$0.26-$0.28 - -$0.240.00%In lineN/A20 up, 1 downAug 4, 2025$1.78M
    Mar 31, 2025-$0.22-$0.20-$0.23 - -$0.17-10.00%MissN/A21 up, 1 downMay 9, 2025$1.53M
    Dec 31, 2024-$0.19-$0.20-$0.20 - -$0.19+5.00%BeatN/A21 up, 0 downMar 12, 2025$1.95M
    Sep 30, 2024-$0.16-$0.20N/A+20.00%BeatN/AN/A0 up, 0 downNov 12, 2024$1.81M
    Jun 30, 2024-$0.22-$0.19-$0.19 - -$0.19-15.79%MissN/A10 up, 0 downAug 6, 2024$1.74M
    Mar 31, 2024-$0.21-$0.15-$0.15 - -$0.15-40.00%MissN/A10 up, 0 downMay 14, 2024$1.51M
    Dec 31, 2023-$0.16-$0.19-$0.20 - -$0.19+15.79%BeatN/A20 up, 0 downMar 6, 2024$1.76M
    Sep 30, 2023-$0.15-$0.15-$0.17 - -$0.140.00%In lineN/A20 up, 0 downNov 6, 2023$1.56M
    Jun 30, 2023-$0.24-$0.30-$0.43 - -$0.17+20.00%BeatN/A20 up, 0 downAug 8, 2023$1.65M
    Mar 31, 2023-$0.53-$0.68-$0.68 - -$0.68+22.06%BeatN/A10 up, 0 downMay 15, 2023$1.24M
    Dec 31, 2022-$0.60-$0.84-$0.84 - -$0.84+28.57%BeatN/A10 up, 0 downMar 30, 2023$1.03M
    Sep 30, 2022-$0.58-$0.73N/A+20.55%BeatN/AN/A0 up, 0 downNov 8, 2022$1.43M
    Jun 30, 2022-$0.59-$0.73-$0.73 - -$0.73+19.18%BeatN/A10 up, 0 downAug 9, 2022$1.53M
    Mar 31, 2022-$0.57-$0.80-$0.80 - -$0.80+28.75%BeatN/A10 up, 0 downMay 10, 2022$1.18M
    Dec 31, 2021-$0.53-$0.78-$0.78 - -$0.78+32.05%BeatN/A10 up, 0 downMar 8, 2022$1.38M
    Sep 30, 2021-$0.53-$0.82-$0.82 - -$0.82+35.37%BeatN/A1N/ANov 9, 2021$1.07M
    Jun 30, 2021-$0.46-$9.45N/A+95.13%BeatN/A1N/AAug 10, 2021$1.04M
    Mar 31, 2021-$0.53-$0.60-$0.60 - -$0.60+11.67%BeatN/A1N/AMay 11, 2021$1.01M
    Dec 31, 2020-$1.20-$0.97-$1.05 - -$0.90-23.71%MissN/A2N/AMar 9, 2021$158000
    Sep 30, 2020-$0.90-$2.70-$4.20 - -$1.20+66.67%BeatN/A2N/ANov 9, 2020$980000
    Jun 30, 2020-$3.00-$5.25-$5.25 - -$5.25+42.86%BeatN/A1N/AAug 5, 2020$313000
    Mar 31, 2020-$6.45-$9.45-$9.45 - -$9.45+31.75%BeatN/A1N/AMay 12, 2020$1.03M
    Dec 31, 2019-$8.55-$8.55-$8.55 - -$8.550.00%In lineN/A1N/AMar 10, 2020$1.01M
    Sep 30, 2019-$18.90-$20.25N/A+6.67%BeatN/A1N/ANov 12, 2019$939000
    Jun 30, 2019-$23.85-$30.00N/A+20.50%BeatN/A1N/AAug 6, 2019$1.35M
    Mar 31, 2019-$57.30-$37.50N/A-52.80%MissN/AN/AN/AMay 14, 2019$415000
    Dec 31, 2018-$5.00N/AN/AN/AN/AN/AN/AN/AFeb 19, 2019$822000
    Sep 30, 2018-$2.50-$2.98N/A+15.97%BeatN/AN/AN/ANov 6, 2018$769000
    Jun 30, 2018-$7.50-$148.75N/A+94.96%BeatN/AN/AN/AAug 6, 2018$1.00M
    Mar 31, 2018-$1.08N/AN/AN/AN/AN/AN/AN/AMay 7, 2018$1.01M
    Dec 31, 2017-$7.38N/AN/AN/AN/AN/AN/AN/AFeb 14, 2018$833000
    Sep 30, 2017-$4,987.50-$59,062.56N/A+91.56%BeatN/AN/AN/ANov 7, 2017$718000
    Jun 30, 2017-$0.21N/AN/AN/AN/AN/AN/AN/AAug 8, 2017$640000
    Mar 31, 2017-$0.65N/AN/AN/AN/AN/AN/AN/AMay 9, 2017$569000
    Dec 31, 2016-$1,531.72N/AN/AN/AN/AN/AN/AN/AFeb 16, 2017$322000
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.79, after -$0.78 the year before. It was -$278,661.63 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.79N/A
    Dec 31, 2024-$0.78N/A
    Dec 31, 2023-$1.08N/A
    Dec 31, 2022-$2.34N/A
    Dec 31, 2021-$2.05N/A
    Dec 31, 2020-$11.55N/A
    Dec 31, 2019-$108.60N/A
    Dec 31, 2018-$16.08N/A
    Dec 31, 2017-$4,995.74N/A
    Dec 31, 2016-$278,661.63N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,3336
    2026Q2Jun 30, 20264,2617
    2026Q1Mar 31, 20263,7357
    2025Q3Sep 30, 20253,9377
    2025Q2Jun 30, 20253,9397
    2025Q1Mar 31, 20253,7987
    2024Q4Dec 31, 20243,7918
    2024Q3Sep 30, 20243,2566

    2026Q3 Earnings Call

    Opening remarks

    Alexandra Grossman LifeSci Advisors Thank you. During this call, management will make forward-looking statements, which are based upon management's current expectations, beliefs, and projections, many of which, by their nature, are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed in such forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K, quarterly report on Form 10-Q, any updates in its current reports on Form 8-K, as well as in InspireMD's press release that accompanies this call, particularly the cautionary statements made in it. During the call today, the company may also discuss certain non-GAAP financial measures. For a more detailed discussion of these non-GAAP financial measures and historical reconciliation to the most closely comparable GAAP measures, please refer to the company's earnings release. This call contains time-sensitive information that is accurate only as of today, November 12, 2026. Except as required by law, InspireMD disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Marvin Slosman, Chief Executive Officer. Marvin, please go ahead.

    Marvin Slosman CEO Thank you, and good afternoon, everyone. The third quarter marked a turning point for InspireMD, and today I am pleased to discuss what we believe is one of the most significant milestones in the company's history. I first want to briefly address the financing announcement we issued today. As you saw in a separate press release issued this afternoon, we have announced a proposed underwritten equity public offering. This financing is intended to support the next phase of our growth, including the full commercialization of CGuard Prime in the U.S. and the broader execution of our strategic priorities. Given that the offering process is ongoing, there are SEC-imposed limitations on what can be discussed beyond the information included in today's announcement. Thus, we are not commenting on the potential size, pricing, timing, and other terms of the transaction during this call. We appreciate your understanding and look forward to providing additional information through the appropriate public disclosures as it becomes available. As I just mentioned, today I'm pleased to discuss what we believe is one of the most significant milestones in our company's history. With FDA approval of our CGuard Prime TransCarotid Stent System for TCAR procedures, we are returning to the U.S.

    Frequently Asked Questions About NSPR

    When is InspireMD's next earnings date?

    InspireMD's next earnings report is expected for Mar 16, 2027.

    Did NSPR beat earnings estimates last quarter?

    Yes. InspireMD reported EPS of -$0.11 for the quarter ended Sep 30, 2026, above the -$0.15 estimate, a 26.67% surprise.

    What EPS do analysts expect from NSPR next quarter?

    The consensus EPS estimate for InspireMD for the quarter ending Dec 31, 2026 is -$0.13 from 5 analysts, with estimates from -$0.14 to -$0.12.

    How often does NSPR beat earnings estimates?

    InspireMD beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +10.58%.